NEW YORK — Drug discovery and bioinformatics startup Pepper Bio said on Thursday that it has raised $6.5 million in seed funding.
The financing round was led by NFX and included Silverton Partners, Merck Digital Sciences Studio, Mana Ventures, Tensility Ventures, and VSC Ventures.
Pepper Bio was founded in 2020 through a Merck-run accelerator program to leverage a multiomics approach — dubbed transomics — to identify new therapeutics, repurpose existing ones, and salvage drugs that are failing in the development process. According to the Boston-based company, its core technology platform analyzes genomic, transcriptomic, proteomic, and phosphoproteomic data to help researchers gain insights into how diseases impact biology.
“This funding will enable us to expand our platform capabilities, further support our current pharma partnerships, and build out our internal pipeline,” Pepper Bio Cofounder and CEO Jon Hu said in a statement.